MarketCapTrends
XENE

Xenon Pharmaceuticals Inc. (XENE)

NASDAQ

Xenon Pharmaceuticals Inc. annual/quarterly shareholder equity history from 2013 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.

  • Xenon Pharmaceuticals Inc. shareholder equity for the quarter ending December 31, 2025 were 581.8M, a 22.94% decrease year-over-year.
  • Xenon Pharmaceuticals Inc. shareholder equity for 2025 were 581.8M, a 22.94% decrease from 2024.
  • Xenon Pharmaceuticals Inc. shareholder equity for 2024 were 754.9M, a 18.65% decrease from 2023.
  • Xenon Pharmaceuticals Inc. shareholder equity for 2023 were 927.9M, a 28.61% increase from 2022.
  • Xenon Pharmaceuticals Inc. shareholder equity for 2022 were 721.5M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
Xenon Pharmaceuticals Inc. Annual Shareholder Equity (Millions of US $)
2025$582
2024$755
2023$928
2022$721
2021$550
2020$171
2019$92
2017$36
2016$64
2015$61
2014$73
2013$-78
Xenon Pharmaceuticals Inc. Quarterly Shareholder Equity (Millions of US $)
2025-12-31$582
2024-12-31$755
2023-12-31$928
2022-12-31$721
2021-12-31$550
2020-12-31$171
2019-12-31$92
2017-12-31$36
2016-12-31$64
2015-12-31$61
2014-12-31$73
2013-12-31$-78

Xenon Pharmaceuticals Inc. Shareholder Equity — FAQ

Xenon Pharmaceuticals Inc. (XENE) shareholder equity over the last 13 years — annual and quarterly figures with year-over-year growth and charts.

Where can I see XENE's shareholder equity history?

The chart and table above show Xenon Pharmaceuticals Inc.'s shareholder equity by year and by quarter, including the growth rate.